255 related articles for article (PubMed ID: 35760287)
1. POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.
Baine MK; Febres-Aldana CA; Chang JC; Jungbluth AA; Sethi S; Antonescu CR; Travis WD; Hsieh MS; Roh MS; Homer RJ; Ladanyi M; Egger JV; Lai WV; Rudin CM; Rekhtman N
J Thorac Oncol; 2022 Sep; 17(9):1109-1121. PubMed ID: 35760287
[TBL] [Abstract][Full Text] [Related]
2. POU2F3: A Sensitive and Specific Diagnostic Marker for Neuroendocrine-low/negative Small Cell Lung Cancer.
Wang Y; Jin Y; Shen X; Zheng Q; Xue Q; Chen L; Lin Y; Li Y
Am J Surg Pathol; 2023 Sep; 47(9):1059-1066. PubMed ID: 37357936
[TBL] [Abstract][Full Text] [Related]
3. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
[TBL] [Abstract][Full Text] [Related]
4. POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic Overlap.
Jimbo N; Ohbayashi C; Takeda M; Fujii T; Mitsui S; Tsukamoto R; Tanaka Y; Itoh T; Maniwa Y
Am J Surg Pathol; 2024 Jan; 48(1):4-15. PubMed ID: 37904277
[TBL] [Abstract][Full Text] [Related]
5. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR
Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
[TBL] [Abstract][Full Text] [Related]
7. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma.
Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK
Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891
[TBL] [Abstract][Full Text] [Related]
8. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
9. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
[TBL] [Abstract][Full Text] [Related]
10. Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56.
Sakakibara R; Kobayashi M; Takahashi N; Inamura K; Ninomiya H; Wakejima R; Kitazono S; Yanagitani N; Horiike A; Ichinose J; Matsuura Y; Nakao M; Mun M; Nishio M; Okumura S; Motoi N; Ito T; Miyazaki Y; Inase N; Ishikawa Y
Am J Surg Pathol; 2020 Jun; 44(6):757-764. PubMed ID: 32118626
[TBL] [Abstract][Full Text] [Related]
11. POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity.
Szczepanski AP; Tsuboyama N; Watanabe J; Hashizume R; Zhao Z; Wang L
Sci Adv; 2022 Oct; 8(40):eabq2403. PubMed ID: 36197978
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T
Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities.
Yamada Y; Belharazem-Vitacolonnna D; Bohnenberger H; Weiß C; Matsui N; Kriegsmann M; Kriegsmann K; Sinn P; Simon-Keller K; Hamilton G; Graeter T; Preissler G; Ott G; Schölch S; Nakajima N; Yoshizawa A; Haga H; Date H; Thomas RK; Petrini I; Giaccone G; Ströbel P; Marx A
Cell Death Dis; 2022 Nov; 13(11):979. PubMed ID: 36402755
[TBL] [Abstract][Full Text] [Related]
14. Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.
Baykara Y; Xiao Y; Yang D; Yakirevich E; Maleki S; Garcia-Moliner M; Wang LJ; Huang CK; Lu S
Virchows Arch; 2022 Jul; 481(1):31-39. PubMed ID: 35357570
[TBL] [Abstract][Full Text] [Related]
15. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
[TBL] [Abstract][Full Text] [Related]
16. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
Kim G; Kim M; Nam EJ; Lee JY; Park E
Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
[TBL] [Abstract][Full Text] [Related]
18. Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3.
Zhong E; Pareja F; Hanna MG; Jungbluth AA; Rekhtman N; Brogi E
Hum Pathol; 2022 Sep; 127():102-111. PubMed ID: 35690220
[TBL] [Abstract][Full Text] [Related]
19. Expression and Clinicopathological Significance of SOX11 in Small-Cell Lung Cancer.
Xinli W; Lixiao W; Baoqi D; Hu H; Qiang Z
Biomed Res Int; 2022; 2022():1707914. PubMed ID: 35402616
[TBL] [Abstract][Full Text] [Related]
20. Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset.
Febres-Aldana CA; Chang JC; Ptashkin R; Wang Y; Gedvilaite E; Baine MK; Travis WD; Ventura K; Bodd F; Yu HA; Quintanal-Villalonga A; Lai WV; Egger JV; Offin M; Ladanyi M; Rudin CM; Rekhtman N
Clin Cancer Res; 2022 Nov; 28(21):4702-4713. PubMed ID: 35792876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
